⚠️

Important: VAERS reports alone cannot determine if a vaccine caused an adverse event. Reports may contain incomplete, inaccurate, or unverified information. Correlation does not equal causation.

Influenza, Seasonal (Flulaval Quadrivalent)×Pain

Pain Reports for Influenza, Seasonal (Flulaval Quadrivalent)

#2 most reported symptom for this vaccine

5,656
Reports
13
Deaths
188
Hospitalizations
0.23
Mortality Rate
%
3.3
Hosp. Rate
%

Pain and Influenza, Seasonal (Flulaval Quadrivalent)

Pain has been reported 5,656 times in association with Influenza, Seasonal (Flulaval Quadrivalent) vaccination in VAERS. This represents 10.9% of all 52,111 reports for this vaccine.

Among these reports, 13 mentioned death (0.23%) and 188 involved hospitalization (3.3%).

Pain is the #2 most frequently reported symptom for Influenza, Seasonal (Flulaval Quadrivalent) out of 2354 total symptoms.

Disclaimer: VAERS reports describe events that occurred after vaccination but do not establish that the vaccine caused the event. Many reported symptoms may be coincidental or related to underlying conditions.

What This Means

Seeing 5,656 reports of Pain after Influenza, Seasonal (Flulaval Quadrivalent) vaccination may seem alarming, but context is critical.

The mortality rate among these reports is very low at 0.23%, suggesting most cases are non-fatal.

Important Context

Association, not causation: These reports show Pain occurred after vaccination, not that the vaccine caused it.
Background rates: Pain may occur naturally at baseline rates in the population, unrelated to vaccination.
Anyone can report: VAERS accepts reports from anyone — patients, parents, healthcare providers — without requiring medical verification.
Denominator missing: VAERS counts reports, not rates per dose. Without knowing how many doses were given, raw counts can be misleading. Learn more →

Quick Facts

Reports:5,656
Deaths:13
Hospitalizations:188
% of Vaccine:10.9%
Rank:#2 of 2354

Data Source

This data comes from the Vaccine Adverse Event Reporting System (VAERS), jointly managed by CDC and FDA.